Prior to the approval of prasugrel, clopidogrel was considered the agent of choice due to safety concerns associated with ticlopidine. A randomized controlled trial comparing prasugrel and ...
MEDLINE e9. Müller C, Büttner HJ, Petersen J, Roskamm H: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.
[16] Ticlopidine and clopidogrel are two antiplatelet agents that can be used in patients who are either refractory to or intolerant of aspirin therapy. Disadvantages of ticlopidine include its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback